Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Therapeutic options for conjunctival neoplasia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The molecular profile of mucosal melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Lymphoma of the Lacrimal Gland - An International Multicenter Retrospective Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Management of Ocular Manifestations of Atopic Dermatitis: A Consensus Meeting Using a Modified Delphi Process

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Ocular adnexal lymphoma in Denmark: a nationwide study of 387 cases from 1980 to 2017

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer


Introduction: Conjunctival neoplasms span from benign lesions to life-threatening malignancies. A wide range of treatment modalities has been developed, spanning from observation, simple excision and topical chemotherapy to advanced surgical techniques combined with adjuvant therapies including cryotherapy, topical and systemic chemotherapy, immune-modulating agents, anti-viral therapy, and radiotherapy.

Areas covered: This review provides an overview of treatment modalities employed in conjunctival neoplasms as well as management guidelines for selected groups of conjunctival tumors. A literature search was performed using the keywords ‘Conjunctival neoplasms’ [MeSH], ‘Conjunctival AND neoplasia’, ‘Conjunctiva AND neoplasia’, ‘Conjunctival tumors’ in combination with ‘Chemotherapy’, ‘Topical chemotherapy’, ‘Mitomycin C’, ‘5-fluorouracil’, ‘Interferon alpha 2b’, ‘anti-VEGF’, ‘Brachytherapy’, ‘Radiation’, ‘Radiotherapy’, ‘Cryotherapy’, ‘Surgery’, ‘Systemic chemotherapy’, and ‘Lymphoma’.

Expert commentary: The efficacy of the different adjuvant therapies is debated. However, there is no doubt that adjuvant therapy reduces the risk of recurrence. Therefore, we recommend that ocular oncologists use an adjuvant therapy together with surgery for conjunctival melanoma. The treatment of malignant conjunctival tumors should be centralized in each country and placed in a few hands. This, combined with large multicenter studies, will provide valuable new information, benefit our patients, and improve the prognosis in the future.
OriginalsprogEngelsk
TidsskriftExpert Review of Ophthalmology
Vol/bind13
Udgave nummer1
Sider (fra-til)17-31
DOI
StatusUdgivet - 2018

ID: 56643792